Status:
COMPLETED
A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
30-65 years
Phase:
PHASE4
Brief Summary
One hundred twenty patients with arterial hypertension and albuminuria (some amount of albumin in urine) are given valsartan 80 mg and then160 mg to normalize blood pressure. Hydrochlorothiazide (diur...
Eligibility Criteria
Inclusion
- Arterial hypertension without previous regular treatment
- Urinary albumin excretion rate above 30 mg / 24h
- 30-65 years old
Exclusion
- Reno-vascular arterial hypertension
- Therapy resistant edema
- Chronic heart failure, angina pectoris
- Diabetes mellitus
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2005
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT00171353
Start Date
July 1 2004
End Date
September 1 2005
Last Update
November 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
Basel, Switzerland